| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Butyryl-L-carnitine chloride targets intestinal transporters, blocking carnitine uptake by the carnitine transporter and glycine transport by the amino acid transporter. It is an inhibitor of these transporters, with IC₅₀ values of 1.5 µM for carnitine uptake and 4.6 mM for glycine transport in human retinal pigment epithelial (HRPE) cells. The compound is used to study transporter function and metabolism.
|
|---|---|
| ln Vitro |
In vitro, Butyryl-L-carnitine chloride inhibits carnitine uptake by the carnitine transporter with an IC₅₀ of 1.5 µM and glycine transport by the amino acid transporter with an IC₅₀ of 4.6 mM in human retinal pigment epithelial (HRPE) cells. The compound is an acylcarnitine that can be isolated from plasma/serum. It is used as an inhibitor in transporter studies.
|
| ln Vivo |
In vivo, Butyryl-L-carnitine chloride is an acylcarnitine found in plasma and serum. As an inhibitor of intestinal transporters, it may affect the absorption of carnitine and other nutrients. However, specific in vivo pharmacological studies have not been extensively reported. The compound is used in metabolism and transporter research.
|
| Enzyme Assay |
In vitro transporter inhibition assays for Butyryl-L-carnitine chloride typically involve measuring the uptake of radiolabeled substrates (such as [³H]carnitine or [¹⁴C]glycine) in cells expressing the transporters. Cells are treated with varying concentrations of the compound, and uptake is measured by scintillation counting. IC₅₀ values are calculated from dose-response curves. The compound's purity is confirmed by HPLC. Purity is ≥95%.
|
| Cell Assay |
In vitro cellular assays for Butyryl-L-carnitine chloride typically utilize human retinal pigment epithelial (HRPE) cells or other cell lines expressing carnitine and amino acid transporters. Cells are treated with the compound and radiolabeled substrates, and transporter activity is measured. The compound inhibits carnitine uptake (IC₅₀ = 1.5 µM) and glycine transport (IC₅₀ = 4.6 mM).
|
| Animal Protocol |
In vivo animal experiments for Butyryl-L-carnitine chloride have not been extensively reported. As an acylcarnitine and transporter inhibitor, potential in vivo studies could include assessment of its effects on carnitine absorption and metabolism. However, such studies have not been published for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Butyryl-L-carnitine chloride are characteristic of acylcarnitines. The compound has a molecular weight of 267.75 g/mol and a molecular formula of C₁₁H₂₂ClNO₄. As a polar acylcarnitine, it is expected to have reasonable water solubility and may be absorbed through carnitine transporters. Storage: under recommended conditions.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Butyryl-L-carnitine chloride has not been extensively documented. As an acylcarnitine, it is expected to have a relatively favorable safety profile. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed.
|
| References |
[1]. Nathalie Lepage, et al. Measurement of plasma/serum acylcarnitines using tandem mass spectrometry. Methods Mol Biol. 2010:603:9-25.
|
| Additional Infomation |
Butyryl-L-carnitine chloride (CAS# 162067-50-7, molecular formula C₁₁H₂₂ClNO₄, molecular weight 267.75) is an acylcarnitine and butyrate ester of carnitine. It inhibits carnitine uptake (IC₅₀ = 1.5 µM) and glycine transport (IC₅₀ = 4.6 mM). Used in transporter research. No clinical trials or regulatory approvals have been identified. Purity ≥95%.
|
| Molecular Formula |
C11H22CLNO4
|
|---|---|
| Molecular Weight |
267.75
|
| Exact Mass |
267.124
|
| CAS # |
162067-50-7
|
| Related CAS # |
Butyryl-L-carnitine-d3 chloride;1334532-21-6;Butyryl-L-carnitine-d7 chloride
|
| PubChem CID |
25105258
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
0.346
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
17
|
| Complexity |
245
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCC(=O)OC(CC(=O)O)C[N+](C)(C)C.[Cl-]
|
| InChi Key |
SRYJSBLNSDMCEA-SBSPUUFOSA-N
|
| InChi Code |
InChI=1S/C11H21NO4.ClH/c1-5-6-11(15)16-9(7-10(13)14)8-12(2,3)4;/h9H,5-8H2,1-4H3;1H/t9-;/m1./s1
|
| Chemical Name |
[(2R)-2-butanoyloxy-3-carboxypropyl]-trimethylazanium;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7348 mL | 18.6741 mL | 37.3483 mL | |
| 5 mM | 0.7470 mL | 3.7348 mL | 7.4697 mL | |
| 10 mM | 0.3735 mL | 1.8674 mL | 3.7348 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
